Quarterly Activities/Appendix 4C Cash Flow Report

• PYC Therapeutics made significant progress in Q2 2026 across its drug development programs
• The company received Orphan Drug Designation for its RP11 drug candidate
• PYC completed enrolment in the Phase 1/2 MAD study for ADOA
• The company expects to provide an update on the ongoing Phase 2 study of VP-001 in RP11 patients in Q4 of CY26
• As of 30 June 2026, the company had $669 million of cash on hand

PYC Therapeutics Ltd (ASX: PYC) provided an update on its progress in Q2 2026. The company's drug development programs saw significant advancements, including Orphan Drug Designation for its RP11 drug candidate by the European Medicines Agency. PYC completed enrolment in the Phase 1/2 MAD study for Autosomal Dominant Optic Atrophy (ADOA), with safety and efficacy data presented at the ARVO conference. The company also released pre-clinical data demonstrating increased target gene expression in the retina 4 months after a single dose of PYC-001. Additionally, PYC presented data from the ongoing Phase 1B MAD study for RP11 at the ARVO conference, showcasing safety and efficacy. PYC expects to provide an update on the ongoing Phase 2 study of VP-001 in RP11 patients in Q4 of CY26. As of 30 June 2026, the company had $669 million of cash on hand.

PYC Therapeutics anticipates providing an update on the ongoing Phase 2 study of VP-001 in RP11 patients in Q4 of CY26, showcasing the extent of the improvement in vision observed in treated eyes.